How pharma wins in the EU Data Act era

The new rules will force pharma organizations to redesign business models, partnerships and platforms. Those that lead will define the rules of Europe’s new data economy.

Download
Collection of digital tablet screens showcasing a whitepaper on how pharma can succeed in the EU’s new data economy, focusing on patient trust, compliance, and digital health transformation.

The EU Data Act (EDA) is a commercial reset for pharma

By September 2025, every pharma organization operating in Europe will be subject to a radically new data regime. The EDA redefines how data is accessed, shared and monetized — placing patients at the center of control and requiring pharma to transform how it engages, partners and delivers value.

What you'll learn

  • How the EDA unlocks real-time, patient-generated data to power evidence-based pricing, real-world evidence (RWE) and transparent innovation.
  • Five strategic transformation zones that will define pharma's future relevance, trust and market access.
  • How to assess your commercial readiness and reduce risk across platforms, contracts and partnerships.

Why it matters now

This is pharma’s moment to lead in a system built on data mobility, fairness, and trust. The EDA, together with initiatives like EHDS, is reshaping how data is accessed, shared, and monetized across Europe. Companies that act now will set the pace and standards others must follow.

Who this paper is for

This paper is a must-read for pharma leaders working at the intersection of strategy, data, regulation, access and outcomes. Whether you're designing PSPs, building RWE platforms or preparing for other data-driven initiatives, this guide will prepare you to lead, not just comply.

Download the whitepaper

Get your copy of How Pharma Wins in the EU’s New Data Economy and start building your roadmap to commercial leadership.